Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials

Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis

(2013) E. Miller et al.   BMJ-British Medical Journal

Immunogenicity and Safety of Varying Dosages of a Monovalent 2009 H1N1 Influenza Vaccine Given With and Without AS03 Adjuvant System in Healthy Adults and Older Persons

(2012) L. A. Jackson et al.   JOURNAL OF INFECTIOUS DISEASES

Safety and Long-term Humoral Immune Response in Adults After Vaccination With an H1N1 2009 Pandemic Influenza Vaccine With or Without AS03 Adjuvant

(2012) Murdo Ferguson et al.   JOURNAL OF INFECTIOUS DISEASES

Randomized, Multicenter Trial of a Single Dose of AS03-adjuvanted or Unadjuvanted H1N1 2009 Pandemic Influenza Vaccine in Children 6 Months to

(2012) Joanne M. Langley et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

AS03 Adjuvanted AH1N1 Vaccine Associated with an Abrupt Increase in the Incidence of Childhood Narcolepsy in Finland

(2012) Hanna Nohynek et al.   PLoS One

Atypical forms of Guillain-Barré syndrome and H1N1-influenza vaccination

(2012) Aasef G. Shaikh et al.   VACCINE

Evaluation of immune response following one dose of an AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or older

(2012) Hideyuki Ikematsu et al.   Human Vaccines & Immunotherapeutics

Safety and persistence of immunological response 6 months after intramuscular vaccination with an AS03-adjuvanted H1N1 2009 influenza vaccine

(2012) Akihiko Saitoh et al.   Human Vaccines & Immunotherapeutics

Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity

(2011) Sandra Morel et al.   VACCINE

Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents

(2011) J. Garcia-Sicilia et al.   VACCINE

AS03A‐Adjuvanted Influenza A (H1N1) 2009 Vaccine for Adults up to 85 Years of Age

(2010) François Roman et al.   CLINICAL INFECTIOUS DISEASES

Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine

(2010) Woolf T Walker et al.   Expert Review of Vaccines

Safety and Cross‐Reactive Immunogenicity of Candidate AS03‐Adjuvanted Prepandemic H5N1 Influenza Vaccines: A Randomized Controlled Phase 1/2 Trial in Adults

(2010) Joanne M. Langley et al.   JOURNAL OF INFECTIOUS DISEASES

Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial

(2010) Karl G Nicholson et al.   LANCET INFECTIOUS DISEASES

An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers

(2010) Abdullah S. Madhun et al.   VACCINE

Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: Preliminary report of an observer-blind, randomised trial

(2009) François Roman et al.   VACCINE